DUBLIN, Aug. 7, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/fmrp7b/investigation) has announced the addition of the "Investigation Report on China's Olanzapine Market, 2010-2019" report to their offering.

According to WHO's statistics,10% of world population suffer from various kinds of mental illnesses. According to the statistics published by the National Center for Mental Health, China-CDC, the number of cases of mental illnesses is more than 100 million, among which 16 million suffer from holergasia. Mental illness has surpassed cancer and become the biggest threat to human health, ranking first in the total burden of disease in China.

As an atypical antipsychotic, olanzapine is mainly used for the treatment of the positive symtoms of schizophrenia and it also has some curative effects on schizophrenia's negative symtoms. Developed on the base of clozapine, the former generation of antipsychotic medication, olanzapine was approved by Food and Drug Administration (FDA) to go on sale in 1996 and its patent held by Eli Lilly expired in 2011. The preparations of olanzapine available in mainland China include domestic Oulaining, Ximin and imported Zyperxa.

As a drug for schizophrenia, olanzapine entered the European and American market in 1996 and then the Chinese market in 1999. In 2003, it was even rated as the first-line drug in the Guidelines for Prevention and Control of Schizophrenia. Olanzapine developed fast after entering China, annual sales value rising from less than CNY 40 million in 2005 to CNY 420 million in 2014 and CAGR during this period reaching 30%. Hanson Pharmaceutical, Changzhou Watson Pharmaceuticals Co., Ltd and Eli Lilly and Company occupy the major market share, among which Hanson Pharmaceutical has the largest market share of about 44% for sales value in 2014.

With the change of life styles and the increased stress in work and life brought about by China's economic development, the incidence of mental illness and psychological problems is growing. Therefore, the market size of olanzapine in China is expected to keep expanding in the next few years.

Key Topics Covered:

1 Related Concepts of Olanzapine

2 Market Profile of Olanzapine in China

3 Survey on Sales Status of Olanzapine in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Olanzapine in China, 2010-2014

5 Survey on Dosage Forms of Olanzapine in China, 2010-2014

6 Reference Price of Olanzapine in Chinese Hospitals in 2014

7 Major Manufacturers of Olanzapine in Chinese Market, 2010-2014

8 Market Outlook of Olanzapine in China, 2015-2019

Companies Mentioned

- Eli Lilly and Company

- Hanson Pharmaceutical

- Changzhou Watson Pharmaceuticals Co., Ltd

For more information visit

http://www.researchandmarkets.com/research/fmrp7b/investigation

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets